TY - JOUR
T1 - Dementia with Lewy bodies
AU - McKeith, Ian
AU - Mintzer, Jacobo
AU - Aarsland, Dag
AU - Burn, David
AU - Chiu, Helen
AU - Cohen-Mansfield, Jiska
AU - Dickson, Dennis
AU - Dubois, Bruno
AU - Duda, John E.
AU - Feldman, Howard
AU - Gauthier, Serge
AU - Halliday, Glenda
AU - Lawlor, Brian
AU - Lippa, Carol
AU - Lopez, Oscar L.
AU - Carlos MacHado, João
AU - O'Brien, John
AU - Playfer, Jeremy
AU - Reid, Wayne
N1 - Funding Information:
IGMcK has received travel sponsorship, honoraria, and research support from Pfizer/Eisai, Novartis, Janssen-Cilag, and Amersham Health. JM has acted as consultant for Eli Lilly, Abbott, AstraZeneca, and Bristol-Myers Squibb and received grants/research support from Eisai America, Inc, Janssen Research Foundation, Novartis, and Pfizer. DA has received travel sponsorship, honoraria, and research support from Pfizer, Novartis, and Janssen-Cilag. JD has received travel support and/or honoraria from Pharmacia, Novartis, and Janssen Pharmaceuticals and research support from Pfizer Pharmaceuticals. HF has received honoraria and research support and has been a paid consultant for Lilly Pharma, Eisai Pfizer, Novartis, and Janssen. SG has acted as consultant to Pfizer, Novartis, and Janssen-Cilag, who are developing drugs useful in DLB. BL has received travel sponsorship, honoraria from Janssen Cilag, Lilly, Pfizer, Astra Zeneca, Wyeth, Organon, Bristol Myers Squibb, and Glaxo Wellcome, and research support from Wyeth. CL is on the speakers' bureau for Pfizer, Novartis, Eisai, OrthoMcNeil, and Janssen (honoraria recipient). JO'B has acted as consultant and/or accepted hospitality and honoraria from Janssen-Cilag, Novartis, Pfizer/Eisai, and Amersham Health. DB, HC, JC-M, DD, BD, GH, OL, JM, JP, and WR have no conflicts of interest to declare.
Funding Information:
This review was the result of an IPA meeting held in Budapest in November 2002. The programme was organised and faculty invited by IPA. The meeting was funded with unrestricted educational grants from Janssen Pharmaceutical Products, LP, Johnson & Johnson Pharmaceutical Services, LLC, Targacept, Inc, AstraZeneca, and Forest Laboratories, Inc. All programming decisions and the resulting review were developed by IPA with no sponsor involvement.
PY - 2004/1/1
Y1 - 2004/1/1
N2 - Dementia with Lewy bodies (DLB) is the second commonest cause of neurodegenerative dementia in older people. It is part of the range of clinical presentations that share a neuritic pathology based on abnormal aggregation of the synaptic protein α-synuclein. DLB has many of the clinical and pathological characteristics of the dementia that occurs during the course of Parkinson's disease. Here we review the current state of scientific knowledge on DLB. Accurate identification of patients is important because they have specific symptoms, impairments, and functional disabilities that differ from those of other common types of dementia. Severe neuroleptic sensitivity reactions are associated with significantly increased morbidity and mortality. Treatment with cholinesterase inhibitors is well tolerated by most patients and substantially improves cognitive and neuropsychiatric symptoms. Clear guidance on the management of DLB is urgently needed. Virtually unrecognised 20 years ago, DLB could within this decade be one of the most treatable neurodegenerative disorders of late life.
AB - Dementia with Lewy bodies (DLB) is the second commonest cause of neurodegenerative dementia in older people. It is part of the range of clinical presentations that share a neuritic pathology based on abnormal aggregation of the synaptic protein α-synuclein. DLB has many of the clinical and pathological characteristics of the dementia that occurs during the course of Parkinson's disease. Here we review the current state of scientific knowledge on DLB. Accurate identification of patients is important because they have specific symptoms, impairments, and functional disabilities that differ from those of other common types of dementia. Severe neuroleptic sensitivity reactions are associated with significantly increased morbidity and mortality. Treatment with cholinesterase inhibitors is well tolerated by most patients and substantially improves cognitive and neuropsychiatric symptoms. Clear guidance on the management of DLB is urgently needed. Virtually unrecognised 20 years ago, DLB could within this decade be one of the most treatable neurodegenerative disorders of late life.
UR - http://www.scopus.com/inward/record.url?scp=9144224226&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=9144224226&partnerID=8YFLogxK
U2 - 10.1016/S1474-4422(03)00619-7
DO - 10.1016/S1474-4422(03)00619-7
M3 - Review article
C2 - 14693108
AN - SCOPUS:9144224226
VL - 3
SP - 19
EP - 28
JO - The Lancet Neurology
JF - The Lancet Neurology
SN - 1474-4422
IS - 1
ER -